Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

4.66 (USD) • At close November 1, 2024
Bedrijfsnaam Vanda Pharmaceuticals Inc.
Symbool VNDA
Munteenheid USD
Prijs 4.66
Beurswaarde 271,630,468
Dividendpercentage 0%
52-weken bereik 3.3 - 6.75
Industrie Biotechnology
Sector Healthcare
CEO Dr. Mihael H. Polymeropoulos M.D.
Website https://www.vandapharma.com

An error occurred while fetching data.

Over Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for

Vergelijkbare Aandelen

UFP Technologies, Inc. logo

UFP Technologies, Inc.

UFPT

272.655 USD

AnaptysBio, Inc. logo

AnaptysBio, Inc.

ANAB

21.68 USD

Vaxxinity, Inc. logo

Vaxxinity, Inc.

VAXX

0.002 USD

Aveanna Healthcare Holdings Inc. logo

Aveanna Healthcare Holdings Inc.

AVAH

4.59 USD

Quantum-Si incorporated logo

Quantum-Si incorporated

QSI

0.768 USD

Orthofix Medical Inc. logo

Orthofix Medical Inc.

OFIX

16.96 USD

Humacyte, Inc. logo

Humacyte, Inc.

HUMA

5.39 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)